Prolonged survival of rat cardiac allograft with proinflammatory cytokine inhibitor

Isao Sano, Takao Takahashi, Takehiko Koji, Heiichiro Udono, Katuyuki Yui, Hiroyoshi Ayabe

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background: Proinflammatory cytokines, such as tumor necrosis factor (TNF-α) and interleukin-1 (IL-1), play important roles in acute allograft rejection. FR167653 is an inhibitor of these cytokines that acts through inhibition of the mitogen-activated protein kinase p38 pathway. We examined the effect of FR167653 on allograft rejection. Methods: We used Brown-Norway and Lewis rats as donors and recipients, respectively. We performed heterotopic cardiac transplantation. The control group consisted of untreated rats. In the experimental groups, recipients were intraperitoneally injected with FR167653 just after operation, followed by daily injection of the drug from Day 1 to 10. We divided 20 rats into 5 groups, which received varying doses of FR167653, ranging from 75 to 300 mg/kg/day. Results: In the control group, the mean graft survival was 6.8 ± 0.3 days. FR167653 at 150 mg/kg/day significantly prolonged the survival period (up to 12.1 ± 1.5 days, p = 0.002). Histologically, FR167653 markedly suppressed cellular infiltration on Day 5 post-transplantation. The serum level of TNF-α in the control group was persistently elevated from 9.3 ± 3.9 pg/ml to 11.3 ± 3.8 pg/ml, whereas FR167653 significantly suppressed the level to

Original languageEnglish
Pages (from-to)583-589
Number of pages7
JournalJournal of Heart and Lung Transplantation
Volume20
Issue number5
DOIs
Publication statusPublished - 2001
Externally publishedYes

Fingerprint

Allografts
Cytokines
Control Groups
Tumor Necrosis Factor-alpha
Heterotopic Transplantation
p38 Mitogen-Activated Protein Kinases
Graft Survival
Heart Transplantation
FR 167653
Interleukin-1
Transplantation
Injections
Serum
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery
  • Transplantation

Cite this

Prolonged survival of rat cardiac allograft with proinflammatory cytokine inhibitor. / Sano, Isao; Takahashi, Takao; Koji, Takehiko; Udono, Heiichiro; Yui, Katuyuki; Ayabe, Hiroyoshi.

In: Journal of Heart and Lung Transplantation, Vol. 20, No. 5, 2001, p. 583-589.

Research output: Contribution to journalArticle

Sano, Isao ; Takahashi, Takao ; Koji, Takehiko ; Udono, Heiichiro ; Yui, Katuyuki ; Ayabe, Hiroyoshi. / Prolonged survival of rat cardiac allograft with proinflammatory cytokine inhibitor. In: Journal of Heart and Lung Transplantation. 2001 ; Vol. 20, No. 5. pp. 583-589.
@article{f2a19ca17b3a426caaa441cc1d6434ee,
title = "Prolonged survival of rat cardiac allograft with proinflammatory cytokine inhibitor",
abstract = "Background: Proinflammatory cytokines, such as tumor necrosis factor (TNF-α) and interleukin-1 (IL-1), play important roles in acute allograft rejection. FR167653 is an inhibitor of these cytokines that acts through inhibition of the mitogen-activated protein kinase p38 pathway. We examined the effect of FR167653 on allograft rejection. Methods: We used Brown-Norway and Lewis rats as donors and recipients, respectively. We performed heterotopic cardiac transplantation. The control group consisted of untreated rats. In the experimental groups, recipients were intraperitoneally injected with FR167653 just after operation, followed by daily injection of the drug from Day 1 to 10. We divided 20 rats into 5 groups, which received varying doses of FR167653, ranging from 75 to 300 mg/kg/day. Results: In the control group, the mean graft survival was 6.8 ± 0.3 days. FR167653 at 150 mg/kg/day significantly prolonged the survival period (up to 12.1 ± 1.5 days, p = 0.002). Histologically, FR167653 markedly suppressed cellular infiltration on Day 5 post-transplantation. The serum level of TNF-α in the control group was persistently elevated from 9.3 ± 3.9 pg/ml to 11.3 ± 3.8 pg/ml, whereas FR167653 significantly suppressed the level to",
author = "Isao Sano and Takao Takahashi and Takehiko Koji and Heiichiro Udono and Katuyuki Yui and Hiroyoshi Ayabe",
year = "2001",
doi = "10.1016/S1053-2498(00)00324-7",
language = "English",
volume = "20",
pages = "583--589",
journal = "Journal of Heart and Lung Transplantation",
issn = "1053-2498",
publisher = "Elsevier USA",
number = "5",

}

TY - JOUR

T1 - Prolonged survival of rat cardiac allograft with proinflammatory cytokine inhibitor

AU - Sano, Isao

AU - Takahashi, Takao

AU - Koji, Takehiko

AU - Udono, Heiichiro

AU - Yui, Katuyuki

AU - Ayabe, Hiroyoshi

PY - 2001

Y1 - 2001

N2 - Background: Proinflammatory cytokines, such as tumor necrosis factor (TNF-α) and interleukin-1 (IL-1), play important roles in acute allograft rejection. FR167653 is an inhibitor of these cytokines that acts through inhibition of the mitogen-activated protein kinase p38 pathway. We examined the effect of FR167653 on allograft rejection. Methods: We used Brown-Norway and Lewis rats as donors and recipients, respectively. We performed heterotopic cardiac transplantation. The control group consisted of untreated rats. In the experimental groups, recipients were intraperitoneally injected with FR167653 just after operation, followed by daily injection of the drug from Day 1 to 10. We divided 20 rats into 5 groups, which received varying doses of FR167653, ranging from 75 to 300 mg/kg/day. Results: In the control group, the mean graft survival was 6.8 ± 0.3 days. FR167653 at 150 mg/kg/day significantly prolonged the survival period (up to 12.1 ± 1.5 days, p = 0.002). Histologically, FR167653 markedly suppressed cellular infiltration on Day 5 post-transplantation. The serum level of TNF-α in the control group was persistently elevated from 9.3 ± 3.9 pg/ml to 11.3 ± 3.8 pg/ml, whereas FR167653 significantly suppressed the level to

AB - Background: Proinflammatory cytokines, such as tumor necrosis factor (TNF-α) and interleukin-1 (IL-1), play important roles in acute allograft rejection. FR167653 is an inhibitor of these cytokines that acts through inhibition of the mitogen-activated protein kinase p38 pathway. We examined the effect of FR167653 on allograft rejection. Methods: We used Brown-Norway and Lewis rats as donors and recipients, respectively. We performed heterotopic cardiac transplantation. The control group consisted of untreated rats. In the experimental groups, recipients were intraperitoneally injected with FR167653 just after operation, followed by daily injection of the drug from Day 1 to 10. We divided 20 rats into 5 groups, which received varying doses of FR167653, ranging from 75 to 300 mg/kg/day. Results: In the control group, the mean graft survival was 6.8 ± 0.3 days. FR167653 at 150 mg/kg/day significantly prolonged the survival period (up to 12.1 ± 1.5 days, p = 0.002). Histologically, FR167653 markedly suppressed cellular infiltration on Day 5 post-transplantation. The serum level of TNF-α in the control group was persistently elevated from 9.3 ± 3.9 pg/ml to 11.3 ± 3.8 pg/ml, whereas FR167653 significantly suppressed the level to

UR - http://www.scopus.com/inward/record.url?scp=0035051722&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035051722&partnerID=8YFLogxK

U2 - 10.1016/S1053-2498(00)00324-7

DO - 10.1016/S1053-2498(00)00324-7

M3 - Article

C2 - 11343986

AN - SCOPUS:0035051722

VL - 20

SP - 583

EP - 589

JO - Journal of Heart and Lung Transplantation

JF - Journal of Heart and Lung Transplantation

SN - 1053-2498

IS - 5

ER -